New York, NY (PRWEB) February 14, 2015
Nearly 1,300 Risperdal lawsuits (http://www.risperdallawsuit2014.com/) alleging male breast growth and other complications are now pending in a consolidated litigation underway in the Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports.
According to court documents posted on the Pennsylvania courts website, a total of 1,278 cases are now included in the proceeding, after being filed on behalf of individuals who allege gynecomastia and other complications. Plaintiffs in these cases similarly accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of failing to adequately warn about side effects that may stem from use of the antipsychotic medication. (In Re: Risperdal Litigation, Case Number 100300296)
We are pleased to see Risperdal lawsuits in Philadelphia continuing to move forward, as our Firm is currently representing numerous individuals whose claims have been filed there. We are actively monitoring updates in the litigation involving this powerful antipsychotic drug, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm is currently offering free and confidential case evaluations to men and young boys who sustained gynecomastia complications allegedly due to use of Risperdal.
In addition to the number of Risperdal lawsuits now filed in the Philadelphia Court of Common Pleas, court documents indicate that the consolidated litigation is steadily moving forward in other ways. The proceedings first bellwether trial got underway in January 2015 with the opening arguments of a case that alleges complications related to gynecomastia, a condition referring to male breast growth. The plaintiff is a 20-year old autistic man who developed breasts as a child, which coincided with his use of Risperdal. (Case No. 1204-01997)
This litigation is not the first time Johnson & Johnson and Janssen have had to defend claims involving the handling of Risperdal. In November 2013, the companies agreed to pay more than $ 2.2 billion to resolve charges from the U.S. Department of Justice that involved its marketing of this and several other medications. Among other claims filed by the federal government were allegations that Johnson & Johnson and Janssen promoted Risperdal for off-label uses not approved by the U.S. Food and Drug Administration (FDA), which included the treatment of children and elderly patients with dementia.
Among other things, the U.S. Department of Justice (http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations) had accused the drug makers of improperly promoting Risperdal for off-label uses, including a number of pediatric indications prior to their 2006 FDA approval. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to treatment with Risperdal may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about Risperdal gynecomastia, please visit Bernstein Liebhard LLPs website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016